found that the small molecule inducer of KLF4, APTO‐253, exerts its anti‐leukemic effects in T‐ALL cells by targeting super‐enhancer (SE)‐driven expression of TAL1, a gene frequently disrupted in T‐ALL. The gene discussed is KLF4; the disease is acute lymphoblastic leukemia.